Compare NC & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NC | LXEO |
|---|---|---|
| Founded | 1913 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.0M | 396.5M |
| IPO Year | 2006 | 2023 |
| Metric | NC | LXEO |
|---|---|---|
| Price | $47.40 | $4.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 8.9K | ★ 937.9K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $104,778,000.00 | $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.15 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.43 | $4.03 |
| 52 Week High | $59.42 | $10.99 |
| Indicator | NC | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 40.07 | 38.16 |
| Support Level | $44.66 | $4.03 |
| Resistance Level | $50.51 | $5.36 |
| Average True Range (ATR) | 1.22 | 0.29 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 8.38 | 7.72 |
NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments: Utility Coal Mining, Contract Mining, and Minerals and Royalties. The Utility Coal Mining segment, operated by North American Coal, manages surface coal mines that are exclusive, long-term fuel providers for power generation companies. The Contract Mining segment, operated by North American Mining, is a provider of a broad range of specialized, long-term contract mining services. The Minerals and Royalties segment, which includes the Catapult Mineral Partners (Catapult) business, acquires and promotes the development of mineral and royalty interests and other related investments.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.